Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02604693 · ClinicalTrials.gov registry record
Exposure in Epigenetic Regulation of Immune Response in Chronic Beryllium Disease (CBD)
A clinical trial, sponsored by National Jewish Health.
- Completed
- Registry status
- 148
- Enrollment target
NCT02604693 is a clinical trial that has completed, run by National Jewish Health. The registered enrollment target is 148 participants.
The verdict
NCT02604693 has completed, sponsored by National Jewish Health.
- COMPLETED
- Registry status
- 148 participants
- Enrollment target
Study Summary
This study will provide important results for each aim, while also providing an integrative transcriptional and epigenomic profile of CBD. In Aim 1 the Investigator will define genome-wide epigenetic alterations of CBD, by determining genes that are DM in pivotal immune cells, in the target organ (CD4+ BAL cells) in CBD compared to BeS and healthy controls. In addition, the Investigator will determine the impact of Be exposure on the methylation profile of CBD and BeS cells compared to each other and normal controls. This information will be used to define DM regions, genes and their networks. Using the cases and controls from Aim 1, we will evaluate the gene-expression from these same subjects in Aim 2 to define functional epigenetic loci based on DE in CD4+ BAL cells with and without Be exposure. The Investigator will also integrate ENCODE/RE methylation, histone modification, and chromatin accessibility data as well as our genome-wide association study (GWAS) data to prioritize epigenetic marks and networks for confirmation and validation in Aim 3. In Aim 3, the Investigator will test the generalizability of their findings, explore the potential of methylation marks as biomarkers of disease in PBMCs and determine if change in methylation of these targets with AZA or folic acid affects key immune and regulatory pathways in a second set of CBD and BeS subjects. Throughout the Aims, the Investigator will use both fresh CD4+ T cells to directly assess disease relevance and Be-stimulated cultured CD4+ T cells (compared to unstimulated cultured T cells) to assess the impact of environmental exposure .
Interventions
- OTHER Nothing
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 148 participants |
| Start Date | 2014-12-14 |
| Est. Completion | 2020-12-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02604693
The ClinicalTrials.gov registry entry for NCT02604693 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 148 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Jewish Health, which has 83 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Nothing is the first listed.
NCT02604693 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02604693 about?
NCT02604693 is a clinical study titled "Exposure in Epigenetic Regulation of Immune Response in Chronic Beryllium Disease (CBD)". This study will provide important results for each aim, while also providing an integrative transcriptional and epigenomic profile of CBD. In Aim 1 the Investigator will define genome-wide epigenetic alterations of CBD, by determining genes that are DM in pivotal immune cells, in the target organ (...
What is the current status of trial NCT02604693?
This trial is currently completed. The enrollment target is 148 participants. The study started on 2014-12-14. Estimated completion is 2020-12-31.
What interventions are being tested in trial NCT02604693?
The interventions under investigation include: Nothing (OTHER).
Who is sponsoring clinical trial NCT02604693?
This trial is sponsored by National Jewish Health, which has 83 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.